New Cancer Screening Recommendation Good for Exact Sciences Says Canaccord

Loading...
Loading...

The 12-page recommendation statement uploaded by the USPSTF [US Preventive Services Task Force] on June 14 bodes well for EXACT Sciences Corporation EXAS, Canaccord Genuity’s Mark Massaro said in a report. He maintained a Buy rating for the company, while raising the price target from $9 to $12.

“In the document, the USPSTF removed the words "recommended" and "alternative" and reiterated that "colorectal cancer screening" is an A rating, and clearly removed any hierarchy of test modalities,” analyst Mark Massaro wrote. He added that this was great news for Exact Sciences and should trigger commercial payor mandates, particularly from United Health and Aetna Inc AET.

Removing Terms

The USPSTF had removed these terms to better communicate that there was convincing evidence that screening for colorectal cancer provides substantial benefit for adults aged 50 to 75 years, and a significant percentage of the eligible US population was not taking advantage of this “effective preventive health strategy,” Massaro mentioned.

Increase Screening

"As such, the screening tests are not presented in any preferred or ranked order; rather, the goal is to maximize the total number of persons who are screened because that will have the largest effect on reducing colorectal cancer deaths,” the analyst quoted the USPSTF as saying.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorLong IdeasPrice TargetReiterationAnalyst RatingsTrading IdeasCanaccord GenuityMark Massaro
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...